Non-Small-Cell Lung
2
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
3 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programA Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in ChinaN/A1 trial
Active Trials
CT
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 programAnlotinib HydrochlorideN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
RocheAtezolizumab
AstraZenecaA Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Chia Tai TianQing Pharmaceutical GroupAnlotinib Hydrochloride
Clinical Trials (3)
Total enrollment: 3,453 patients across 3 trials
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Start: Apr 2018Est. completion: Dec 2025453 patients
Phase 3Completed
NCT07316062AstraZenecaA Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Start: Apr 2026Est. completion: Apr 20293,000 patients
N/ANot Yet Recruiting
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
Start: Mar 2019Est. completion: Dec 2020
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space